Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism

Nature

Volumn 443, Issue 7113, 2006, Pages 870-874

  Shen, Yuequan ^a   Joachimiak, Andrzej ^b   Rich Rosner, Marsha ^a   Tang, Wei Jen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Structural Biology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CATALYST ACTIVITY; GLUCOSE; POLYPEPTIDES; SUBSTRATES;

ALLOSTERIC REGULATION; BINDING CAVITY; CONFORMATIONAL CHANGES; MUTATION;

INSULIN;

AMYLOID BETA PROTEIN[1-40]; INSULIN; INSULINASE;

CATALYSIS; ENZYME ACTIVITY; GLUCOSE; HORMONE; MUTATION; PEPTIDE; RODENT;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME ANALYSIS; ENZYME BINDING; ENZYME MECHANISM; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; HYDROPHOBICITY; INSULIN DEGRADATION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STRUCTURE ANALYSIS;

RODENTIA;

EID: 33750302461     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05143     Document Type: Article

References (30)

1. Duckworth, W. C., Bennett, R. G. & Hamel, F. G. Insulin degradation: progress and potential. Endocr. Rev. 19, 608-624 (1998).
2. Kurochkin, I. V. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci. 26, 421-425 (2001).
3. Bennett, R. G., Duckworth, W. C. & Hamel, F. G. Degradation of amylin by insulin-degrading enzyme. J. Biol. Chem. 275, 36621-36625 (2000).
4. Farris, W. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA 100, 4162-4167 (2003).
5. Farris, W. et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β-protein. Am. J. Pathol. 164, 1425-1434 (2004).
6. Leissring, M. A. et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093 (2003).
7. Miller, B. C. et al. Amyloid-β peptide levels in brain are inversely correlated with insulin activity levels in vivo. Proc. Natl Acad. Sci. USA 100, 6221-6226 (2003).
8. Selkoe, D. J. Clearing the brain's amyloid cobwebs. Neuron 32, 177-180 (2001).
9. Tanzi, R. E. & Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555 (2005).
10. Mirsky, I. A. & Broth-Kahn, R. H. The inactivation of insulin by tissue extracts. I. The distribution and properties of insulin inactivating extracts (insulinase). Arch. Biochem. 20, 1-9 (1949).
11. Adames, N., Blundell, K., Ashby, M. N. & Boone, C. Role of yeast insulin-degrading enzyme homologs in propheromone processing and bud site selection. Science 270, 464-467 (1995).
12. Fujita, A. et al. A yeast gene necessary for bud-site selection encodes a protein similar to insulin-degrading enzymes. Nature 372, 567-570 (1994).
13. Perlman, R. K. & Rosner, M. R. Identification of zinc ligands of the insulin-degrading enzyme. J. Biol. Chem. 269, 33140-33145 (1994).
14. Li, P., Kuo, W-L., Yousef, M., Rosner, M. R. & Tang, W-J. The C-terminal domain of human insulin degrading enzyme is required for the dimerization and substrate recognition. Biochem. Biophys. Res. Commun. 343, 1032-1037 (2006).
15. Becker, A. B. & Roth, R. A. An unusual active site identified in a family of zinc metalloendopeptidases. Proc. Natl Acad. Sci. USA 89, 3835-3839 (1992).
16. Maskos, K. in Handbook of Metalloproteins (eds Messerschmidt, A., Dode, W. & Cygler, M.) 190-198 (John Wiley & Sons, 2004).
17. Lawrence, M. C. & Colman, P. M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946-950 (1993).
18. Dombkowski, A. A. Disulfide by Design: a computational method for the rational design of disulfide bonds in proteins. Bioinformatics 19, 1852-1853 (2003).
19. Song, E. S., Juliano, M. A., Juliano, L. & Hersh, L. B. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J. Biol. Chem. 278, 49789-49794 (2003).
20. Chothia, C., Lesk, A. M., Dodson, G. G. & Hodgkin, D. C. Transmission of conformational change in insulin. Nature 302, 500-505 (1983).
21. Sasaki, K., Dockerill, S., Adamiak, D. A., Tickle, I. J. & Blundell, T. X-ray analysis of glucagon and its relationship to receptor binding. Nature 257, 751-757 (1975).
22. Braun, W., Wider, G., Lee, K. H. & Wuthrich, K. Conformation of glucagon in a lipid-water interphase by 1H nuclear magnetic resonance. J. Mol. Biol. 169, 921-948 (1983).
23. Coles, M., Bicknell, W., Watson, A. A., Fairlie, D. P. & Craik, D. J. Solution structure of amyloid β-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 37, 11064-11077 (1998).
24. Mascioni, A., Porcelli, F., Ilangovan, U., Ramamoorthy, A. & Veglia, G. Conformational preferences of the amylin nucleation site in SDS micelles: an NMR study. Biopolymers 69, 29-41 (2003).
25. Sticht, H. et al. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur. J. Biochem. 233, 293-298 (1995).
26. Leissring, M. A. et al. Kinetics of amyloid β-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J. Biol. Chem. 278, 37314-37320 (2003).
27. Taylor, A. B. et al. Crystal structures of mitochondrial processing peptidase reveal the mode for specific cleavage of import signal sequences. Structure 9, 615-625 (2001).
28. Luciano, P. & Geli, V. The mitochondrial processing peptidase: function and specificity. Experientia 52, 1077-1082 (1996).
29. La Fortelle, E. & Bricogne, G. Maximum-likelihood heavy-atom parameter refinement in the MIR and MAD methods. Methods Enzymol. 276, 472-494 (1997).
30. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).